drugset / Trial / NCT02919371
Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
NaSingle-groupOpen-labelTreatment
Summary
Combined sunitinib and bevacizumab in advanced renal cell carcinoma.
Timeline
- Start
- 2014-12
- Primary completion
- 2020-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |